<DOC>
	<DOCNO>NCT02633683</DOCNO>
	<brief_summary>The objective trial evaluate long-term efficacy safety HORIZANT ( Gabapentin Enacarbil ) 600 mg daily , treatment RLS adolescent ( 13 17 year age ) diagnose moderate-to-severe primary RLS .</brief_summary>
	<brief_title>An Extension Study Evaluate Efficacy Safety HORIZANT Adolescents With Moderate-to-Severe Primary RLS</brief_title>
	<detailed_description />
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Patients complete participation 1 2 precede study HORIZANT , Study XP108 Study XP109 . Negative pregnancy test female childbearing potential . Male patient able father child must agree use barrier method ( male condom , female condom , diaphragm , cervical cap ) spermicide least 30 day prior dose throughout study . Fertile , sexually active patient must agree use 2 medically accept method contraception Patients must willing refrain use drug likely affect RLS sleep assessment duration study . Signed patient parent ( legal guardian ) Institutional Review Board ( IRB ) approve assent consent form study procedure carry Patients , opinion investigator , would noncompliant study visit schedule , procedure , medication administration Patients develop clinically significant unstable medical condition , would otherwise unsuitable participation continuation study gabapentin enacarbil</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Restless Legs Syndrome</keyword>
	<keyword>RLS</keyword>
</DOC>